Symbols

DXCM

Dexcom·NASDAQ

--(--)

DXCM fundamentals

DXCM Q4 2025 Earnings

Dexcom (DXCM) released its earnings on Feb 12, 2026: revenue was 1.26B (YoY +13.12%), beat estimates; EPS was 0.68 (YoY +51.11%), beat estimates.

Revenue / YoY

1.26B

+13.12%

EPS / YoY

0.68

+51.11%

Report date

Feb 12, 2026

DXCM Earnings Call Summary for Q4,2025

Revenue Growth: Q4 2025 up 13% to $1.26 billion, with 2026 guidance of 11-13% growth.
Product Innovation: G7 15 Day launched globally, improving accuracy and wear time.
Strategic Expansion: Targeting 12 million Medicare beneficiaries for type 2 non-insulin coverage, with 2026 RCT data.
Financial Strength: $2 billion cash, 2025 free cash flow >$1 billion, and 2026 gross margin 63-64%.
International Ambition: Ireland manufacturing to support global expansion, with Europe/Asia-Pacific growth targeting 15-18%.

Earnings

EPS

Revenue

Revenue & Expenses

DXCM has released its 2025 Q4 earnings report, with revenue of 1.26B, reflecting a YoY change of 13.12%, and net profit of 267.30M, showing a YoY change of 76.20%. The Sankey diagram below clearly presents DXCM's revenue sources and cost distribution.

Key Indicators

Dexcom (DXCM) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Dexcom (DXCM)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Dexcom (DXCM)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Dexcom (DXCM)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown